Why is Sino Biopharmaceutical stock surging today?

Sino Biopharmaceutical stock surged 8.4% to HK$5.58 on Thursday after the company unveiled a transformative option and licensing agreement with Germany’s Boehringer Ingelheim.

The deal covers six preclinical oncology programs built on antibody-drug conjugate and T-cell engager technologies. Under the terms of the deal, Sino Biopharmaceutical will receive $358 million in upfront and near-term payments, with the potential to earn up to $7 billion in additional option-exercise, development, regulatory, and commercial milestone payments, plus tiered royalties reaching double-digit percentages on future product sales — the largest licensing deal in the company’s history by potential value.

The agreement deepens what is already a multi-year relationship between the two companies, representing their second oncology collaboration and coming shortly after Boehringer opened a new R&D center in Shanghai.

Sino Biopharmaceutical will lead early-stage development across all six programs, with Boehringer retaining the option to assume exclusive development, manufacturing, and commercialization rights after agreed clinical milestones are met.

The deal also reflects a broader wave of Western pharma interest in Chinese biotech assets, as Sanofi, GSK, and AstraZeneca have all signed licensing agreements with Sino Biopharmaceutical in 2026.

The news lifted the entire Hong Kong innovative drug sector, with multiple pharma peers posting strong gains in sympathy, reinforcing the view that China’s license-out deal momentum — which has nearly matched the full-year 2025 record through just the first three quarters of 2026 — remains a powerful structural tailwind for the space.

The Hang Seng Index itself advanced approximately 1.7% today, aided by a globally risk-on tone following U.S. midterm election results that reduced policy uncertainty and boosted investor appetite for equities across Asia.